Currently released so far... 97115 / 251,287
Articles
Brazil
Sri Lanka
United Kingdom
Sweden
00. Editorial
United States
Latin America
Egypt
Jordan
Yemen
Thailand
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
2011/05/01
2011/05/02
2011/05/03
2011/05/04
2011/05/05
2011/05/06
2011/05/07
2011/05/09
2011/05/10
2011/05/11
2011/05/12
2011/05/13
2011/05/14
2011/05/15
2011/05/16
2011/05/17
2011/05/18
2011/05/19
2011/05/20
2011/05/21
2011/05/22
2011/05/23
2011/05/24
2011/05/25
2011/05/26
2011/05/27
2011/05/28
2011/05/29
2011/05/30
2011/05/31
2011/06/01
2011/06/02
2011/06/03
2011/06/04
2011/06/05
2011/06/06
2011/06/07
2011/06/08
2011/06/09
2011/06/10
2011/06/11
2011/06/12
2011/06/13
2011/06/14
2011/06/15
2011/06/16
2011/06/17
2011/06/18
2011/06/19
2011/06/20
2011/06/21
2011/06/22
2011/06/23
2011/06/24
2011/06/25
2011/06/26
2011/06/27
2011/06/28
2011/06/29
2011/06/30
2011/07/01
2011/07/02
2011/07/04
2011/07/05
2011/07/06
2011/07/07
2011/07/08
2011/07/10
2011/07/11
2011/07/12
2011/07/13
2011/07/14
2011/07/15
2011/07/16
2011/07/17
2011/07/18
2011/07/19
2011/07/20
2011/07/21
2011/07/22
2011/07/23
2011/07/25
2011/07/27
2011/07/28
2011/07/29
2011/07/31
2011/08/01
2011/08/02
2011/08/03
2011/08/05
2011/08/06
2011/08/07
2011/08/08
2011/08/10
2011/08/11
2011/08/12
2011/08/13
2011/08/15
2011/08/16
2011/08/17
2011/08/19
2011/08/21
2011/08/22
2011/08/23
2011/08/24
2011/08/25
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Antananarivo
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Alexandria
Consulate Adana
American Institute Taiwan, Taipei
Embasy Bonn
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Brazzaville
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangui
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Belfast
Consulate Barcelona
Embassy Cotonou
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chiang Mai
Consulate Chennai
Consulate Chengdu
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
DIR FSINFATC
Consulate Dusseldorf
Consulate Durban
Consulate Dubai
Consulate Dhahran
Embassy Guatemala
Embassy Grenada
Embassy Georgetown
Embassy Gaborone
Consulate Guayaquil
Consulate Guangzhou
Consulate Guadalajara
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Hong Kong
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kolonia
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Krakow
Consulate Kolkata
Consulate Karachi
Consulate Kaduna
Embassy Luxembourg
Embassy Lusaka
Embassy Luanda
Embassy London
Embassy Lome
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy Libreville
Embassy La Paz
Consulate Leipzig
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Mission Geneva
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Mogadishu
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maseru
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Merida
Consulate Melbourne
Consulate Matamoros
Consulate Marseille
Embassy Nouakchott
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Nuevo Laredo
Consulate Naples
Consulate Naha
Consulate Nagoya
Embassy Pristina
Embassy Pretoria
Embassy Praia
Embassy Prague
Embassy Port Of Spain
Embassy Port Moresby
Embassy Port Louis
Embassy Port Au Prince
Embassy Podgorica
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Ponta Delgada
Consulate Peshawar
REO Mosul
REO Kirkuk
REO Hillah
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Surabaya
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy Tirana
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
Consulate Thessaloniki
USUN New York
USMISSION USTR GENEVA
USEU Brussels
US Office Almaty
US Mission Geneva
US Mission CD Geneva
US Interests Section Havana
US Delegation, Secretary
US Delegation FEST TWO
UNVIE
UN Rome
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vientiane
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
AF
ADANA
ASEC
AFIN
AMGT
AE
AORC
AID
AR
AO
AU
ASEAN
AGOA
AFGHANISTAN
AFFAIRS
AMED
APER
ASECARP
APEC
AEMR
AS
AA
ANET
AFLU
ABLD
AL
ASUP
AJ
APECO
AMER
ABUD
AODE
AM
AFSN
AESC
AND
AG
ALOW
AROC
AVIANFLU
ATRN
ACOA
AEGR
AMGMT
AADP
AFSI
ACABQ
APRM
AZ
AIDS
ASE
AGAO
ADCO
ABDALLAH
ARF
AIDAC
ACOTA
ASCH
AC
ASEG
AGR
ACS
AMCHAMS
AN
AMIA
ASIG
ADPM
ADB
ANARCHISTS
ALOWAR
ARM
AUC
AINF
AINT
AORG
AY
AVIAN
AMEDCASCKFLO
AK
ARSO
ARABBL
ASO
ANTITERRORISM
ARABL
AOWC
AGRICULTURE
ALJAZEERA
AMTC
AFINM
AOCR
ABER
ARR
AFPK
ASSEMBLY
ASSK
AZE
AORCYM
AINR
AGMT
AEC
ACKM
APRC
AIN
ASCC
AFPREL
ASED
APERTH
ASFC
ASECTH
AFSA
AOMS
AORCO
ANTXON
ARC
AFAF
ADIP
AIAG
AFARI
AEMED
AORL
AX
ASECAF
AOPC
ASECAFIN
AFZAL
APCS
AMB
AGUIRRE
AEMRASECCASCKFLOMARRPRELPINRAMGTJMXL
AIT
ARCH
AMEX
ALI
AQ
ATFN
AMBASSADOR
AORCD
AVIATION
ARAS
AINFCY
ACBAQ
AOPR
AREP
ALEXANDER
ATRD
AEIR
AOIC
ABLDG
ASEX
AFR
ASCE
ATRA
ASEK
AER
ALOUNI
AMCT
AVERY
APR
AMAT
AEMRS
ASPA
AFU
AMG
ATPDEA
ALL
AECL
ACAO
ASECKFRDCVISKIRFPHUMSMIGEG
AORD
AFL
AME
ADM
ASECPHUM
AGIT
ABT
ASECVE
AGUILAR
AT
ABMC
ALZUGUREN
ANGEL
ASR
ANTONIO
BMGT
BEXP
BM
BG
BL
BA
BR
BTA
BO
BY
BBSR
BLUE
BK
BF
BTIO
BELLVIEW
BE
BU
BN
BH
BD
BC
BTC
BILAT
BT
BX
BRUSSELS
BP
BB
BRPA
BUSH
BURMA
BMENA
BESP
BIT
BBG
BGD
BMEAID
BAGHDAD
BEN
BIO
BMOT
BWC
BLUNT
BURNS
BUT
BGMT
BAIO
BCW
BOEHNER
BFIF
BOL
BASHAR
BIMSTEC
BOU
BIDEN
BZ
BFIN
BTRA
BI
BHUM
BOIKO
BERARDUCCI
BOUCHAIB
BORDER
BEXPC
BTIU
BTT
BIOS
BEXB
BGPGOV
BOND
BLR
CE
CG
CH
CVR
CASC
CU
CI
CD
CO
CDG
CB
CJAN
CPAS
COM
CVIS
CMGT
CT
CENTCOM
CNARC
CTERR
COUNTER
CHIEF
CDC
CTR
CBW
COUNTRY
CLEARANCE
CY
CA
CM
CS
CWC
CN
CITES
CF
CWG
CIVS
CFIS
CASCC
CROATIA
CONS
COUNTERTERRORISM
CASA
COE
CJ
CHR
CODEL
CR
CBC
CACS
CHERTOFF
CAS
CONTROL
CONDITIONS
CONDOLEEZZA
CITEL
CV
CLINTON
CHG
CZ
CON
CTBT
CEN
CRIMES
COMMERCE
CLOK
CRISTINA
CFED
CARC
CND
CTM
CARICOM
COUNTRYCLEARANCE
CBTH
CHINA
CSW
CICTE
CJUS
CYPRUS
CW
CAMBODIA
CENSUS
CIDA
CRIME
CBG
CBE
CMGMT
CAIO
CEC
CARSON
CPCTC
CEDAW
COMESA
CVIA
CWCM
CEA
COSI
CAPC
CGEN
COPUOS
CGOPRC
COETRD
CKGR
CFE
CQ
CITT
CIC
CARIB
CVIC
CLO
CAFTA
CVISU
CHRISTOPHER
CACM
CIAT
CDB
CIS
CUL
CHAO
CNC
CL
CSEP
COMMAND
CENTER
COL
CAN
CAJC
CUIS
CONSULAR
CLMT
CIA
CBSA
CEUDA
CAC
CROS
CIO
CPUOS
CKOR
CVPR
CONG
CONTROLS
CEPTER
CVISCMGTCASCKOCIASECPHUMSMIGKIRF
CDCE
DPOL
DEMARCHE
DHS
DR
DA
DISENGAGEMENT
DEMOCRATIC
DEFENSE
DJ
DY
DARFUR
DHRF
DEA
DTRO
DPRK
DO
DARFR
DOC
DRL
DK
DOJ
DTRA
DOMESTIC
DAC
DOD
DEAX
DIEZ
DEOC
DELTAVIOLENCE
DCOM
DMINE
DRC
DCG
DPKO
DOMESTICPOLITICS
DE
DB
DOT
DEPT
DOE
DHLAKAMA
DHSX
DS
DKEM
DAO
DCM
DANIEL
DEM
DAVID
DCRM
ETRD
EAGR
ETTC
EAID
ECON
EFIN
ECIN
EINV
ELAB
EAIR
ENRG
EPET
EWWT
ECPS
EIND
EMIN
ELTN
EC
ETMIN
EUC
EZ
ET
ELECTIONS
ENVR
EU
EUN
EG
EINT
ER
ECONOMICS
ES
EMS
ENIV
EEB
EN
ECE
ECOSOC
EK
ENVIRONMENT
EFIS
EI
EWT
ENGRD
ECPSN
EXIM
EIAD
ERIN
ECPC
EDEV
ENGY
ECTRD
EPA
ESTH
ECCT
EINVECON
ENGR
ERTD
EUR
EAP
EWWC
ELTD
EL
EXIMOPIC
EXTERNAL
ETRDEC
ESCAP
ECO
EGAD
ELNT
ECONOMIC
ENV
ETRN
EIAR
EUMEM
ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID
EREL
ECOM
ECONETRDEAGRJA
ETCC
ETRG
ECONOMY
EMED
ETR
ENERG
EITC
EFINOECD
EURM
EENG
ERA
EXPORT
ENRD
ECONEINVETRDEFINELABETRDKTDBPGOVOPIC
EGEN
EBRD
EVIN
ETRAD
ECOWAS
EFTA
ECONETRDBESPAR
EGOVSY
EPIN
EID
ECONENRG
EDRC
ESENV
ETT
EB
ENER
ELTNSNAR
ECHEVARRIA
ETRC
EPIT
EDUC
ESA
EFI
ENRGY
ESCI
EE
EAIDXMXAXBXFFR
EETC
ECIP
EIAID
EIVN
EBEXP
ESTN
EING
EGOV
ETRA
EPETEIND
ELAN
ETRDGK
EAIDRW
ETRDEINVECINPGOVCS
EPEC
ENVI
ELN
EAG
EPCS
EPRT
EPTED
ETRB
EUM
EAIDS
EFIC
EFINECONEAIDUNGAGM
EAIDAR
ESF
EIDN
ELAM
EDU
EV
EAIDAF
ECN
EDA
EXBS
EINTECPS
ENRGTRGYETRDBEXPBTIOSZ
EPREL
EAC
EINVEFIN
ETA
EAGER
EINDIR
ECA
ECLAC
ELAP
EITI
EUCOM
ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID
EARG
ELDIN
EINVKSCA
ENNP
EFINECONCS
EFINTS
ECCP
ETC
EAIRASECCASCID
EINN
ETRP
EAIDNI
EFQ
ECOQKPKO
EGPHUM
EBUD
ECONEINVEFINPGOVIZ
ENERGY
ELB
EINDETRD
EMI
ECONEFIN
EIB
EURN
ETRDEINVTINTCS
EIN
EFIM
ETIO
ELAINE
EMN
EATO
EWTR
EIPR
EINVETC
ETTD
ETDR
EIQ
ECONCS
EPPD
ENRGIZ
EISL
ESPINOSA
ELEC
EAIG
ESLCO
EUREM
ENTG
ERD
EINVECONSENVCSJA
EEPET
EUNCH
ECINECONCS
ETRO
ETRDECONWTOCS
ECUN
EFND
EPECO
EAIRECONRP
ERGR
ETRDPGOV
ECPN
ENRGMO
EPWR
EET
EAIS
EAGRE
EDUARDO
EAGRRP
EAIDPHUMPRELUG
EICN
ECONQH
EVN
EGHG
ELBR
EINF
EAIDHO
EENV
ETEX
ERNG
ED
FR
FREEDOM
FINREF
FJ
FI
FRELIMO
FOREIGN
FAA
FETHI
FAS
FTAA
FRB
FAO
FCS
FINANCE
FWS
FTA
FEMA
FDA
FLU
FRANCISCO
FBI
FORCE
FO
FARC
FK
FT
FCSC
FAC
FM
FMGT
FINV
FCSCEG
FARM
FERNANDO
FINR
FIN
FINE
FIR
FDIC
FOR
FOI
FCUL
FKLU
FMLN
FISO
FIXED
GM
GMUS
GG
GR
GE
GAZA
GT
GH
GZ
GJ
GLOBAL
GV
GABY
GOI
GA
GCC
GB
GY
GATT
GC
GUAM
GEORGE
GTIP
GOV
GOMEZ
GUTIERREZ
GL
GKGIC
GF
GU
GWI
GARCIA
GTMO
GN
GANGS
GIPNC
GAERC
GREGG
GUILLERMO
GASPAR
GERARD
GI
HK
HR
HUMANR
HUMAN
HO
HA
HUMANRIGHTS
HU
HHS
HIV
HUM
HRKAWC
HILLEN
HILLARY
HDP
HUMRIT
HSTC
HUMANITARIAN
HCOPIL
HADLEY
HURI
HL
HRETRD
HOURANI
HG
HARRIET
HESHAM
HI
HNCHR
HARRY
HRECON
HRC
HOSTAGES
HEBRON
HUMOR
HSWG
HYMPSK
HECTOR
HN
HYDE
HUD
HRPGOV
HIGHLIGHTS
ID
ILC
IS
IZ
ICAO
IMO
ITU
IR
IAEA
ICRC
IPROP
IT
IBRD
ISRAELI
IRAQI
ISSUES
ITRA
IV
IO
IGAD
IRAQ
IN
IMF
ICTR
ISCON
IADB
IDB
IEA
INR
IWC
ICCAT
ILO
INMARSAT
IOM
ICJ
IQ
ISPA
ITRD
IPR
INTELSAT
ISN
IAHRC
INTERNAL
IFAD
IICA
IHO
IRAN
IL
IRCE
IC
INTELLECTUAL
IRM
IE
ICTY
IDLI
IFO
ISCA
INF
INL
ISRAEL
INV
IBB
INFLUENZA
ISPL
ITER
ITIA
INRA
ISAF
IACHR
INTERPOL
IFR
IRS
INRB
IEF
ISAAC
ICC
INDO
IIP
IATTC
INAUGURATION
IND
INS
IZPREL
IACI
IEFIN
INNP
ILAB
IA
IMTS
ITALY
ITALIAN
IFIN
IRAJ
IX
ICG
IF
ITPHUM
ITA
IP
IACW
IK
IUCN
IZEAID
IRPE
IDA
ISLAMISTS
ITF
INRO
IBET
IDP
IRC
ISO
ICES
IRMO
ITPGOV
IQNV
IMSO
IRDB
IMET
INCB
IFRC
JA
JO
JP
JM
JCIC
JOHN
JE
JEFFERY
JS
JUS
JN
JOHNNIE
JAMES
JKUS
JOSEPH
JML
JAWAD
JSRP
JIMENEZ
JOSE
JKJUS
JK
JAPAN
KMDR
KPAO
KPKO
KJUS
KCRM
KGHG
KFRD
KWMN
KDEM
KTFN
KHIV
KGIC
KIDE
KSCA
KNNP
KHUM
KIPR
KSUM
KISL
KIRF
KCOR
KRCM
KPAL
KWBG
KN
KS
KOMC
KSEP
KFLU
KPWR
KTIA
KSEO
KMPI
KHLS
KICC
KSTH
KMCA
KVPR
KPRM
KE
KU
KZ
KFLO
KSAF
KTIP
KTEX
KBCT
KOCI
KOLY
KOR
KAWC
KACT
KUNR
KTDB
KSTC
KLIG
KSKN
KNN
KCFE
KCIP
KGHA
KHDP
KPOW
KUNC
KDRL
KV
KPREL
KCRS
KPOL
KRVC
KRIM
KGIT
KWIR
KT
KIRC
KOMO
KRFD
KUWAIT
KG
KFIN
KSCI
KTFIN
KFTN
KGOV
KPRV
KSAC
KGIV
KCRIM
KPIR
KSOC
KBIO
KW
KGLB
KMWN
KPO
KFSC
KSEAO
KSTCPL
KSI
KPRP
KREC
KFPC
KUNH
KCSA
KMRS
KNDP
KR
KICCPUR
KPPAO
KCSY
KTBT
KCIS
KNEP
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KNNB
KGCC
KINR
KPOP
KMFO
KENV
KNAR
KVIR
KDRG
KDMR
KFCE
KNAO
KDEN
KGCN
KICA
KIMMITT
KMCC
KLFU
KMSG
KSEC
KUM
KCUL
KMNP
KSMT
KCOM
KOMCSG
KSPR
KPMI
KRAD
KIND
KCRP
KAUST
KWAWC
KTER
KCHG
KRDP
KPAS
KITA
KTSC
KPAOPREL
KWGB
KIRP
KJUST
KMIG
KLAB
KTFR
KSEI
KSTT
KAPO
KSTS
KLSO
KWNN
KPOA
KHSA
KNPP
KPAONZ
KBTS
KWWW
KY
KJRE
KPAOKMDRKE
KCRCM
KSCS
KWMNCI
KESO
KWUN
KPLS
KIIP
KEDEM
KPAOY
KRIF
KGICKS
KREF
KTRD
KFRDSOCIRO
KTAO
KJU
KWMNPHUMPRELKPAOZW
KEN
KO
KNEI
KEMR
KKIV
KEAI
KWAC
KRCIM
KWCI
KFIU
KWIC
KCORR
KOMS
KNNO
KPAI
KBWG
KTTB
KTBD
KTIALG
KILS
KFEM
KTDM
KESS
KNUC
KPA
KOMCCO
KCEM
KRCS
KWBGSY
KNPPIS
KNNPMNUC
KWN
KERG
KLTN
KALM
KCCP
KSUMPHUM
KREL
KGH
KLIP
KTLA
KAWK
KWMM
KVRP
KVRC
KAID
KSLG
KDEMK
KX
KIF
KNPR
KCFC
KFTFN
KTFM
KPDD
KCERS
KMOC
KDEMAF
KMEPI
KEMS
KDRM
KEPREL
KBTR
KEDU
KNP
KIRL
KNNR
KMPT
KISLPINR
KTPN
KA
KJUSTH
KPIN
KDEV
KTDD
KAKA
KFRP
KWNM
KTSD
KINL
KJUSKUNR
KWWMN
KECF
KWBC
KPRO
KVBL
KOM
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KEDM
KFLD
KLPM
KRGY
KNNF
KICR
KIFR
KM
KWMNCS
KAWS
KLAP
KPAK
KDDG
KCGC
KID
KNSD
KMPF
KPFO
KDP
KCMR
KRMS
KNPT
KNNNP
KTIAPARM
KDTB
KNUP
KPGOV
KNAP
KNNC
KUK
KSRE
KREISLER
KIVP
KQ
KTIAEUN
KPALAOIS
KRM
KISLAO
KWM
KFLOA
LE
LU
LH
LA
LG
LO
LY
LANTERN
LI
LABOR
LORAN
LTTE
LT
LAS
LAB
LAW
LVPR
LARREA
LEBIK
LAURA
LS
LOTT
LOVE
LR
LEON
LAVIN
LGAT
LV
LAOS
LOG
LN
LB
MOPS
MO
MARR
ML
MASS
MZ
MR
MNUC
MX
MV
MCC
MY
MEDIA
MTCRE
MG
MCAP
MOPPS
MP
MI
MK
MC
MD
MA
MU
MASC
MW
MT
MEPP
MN
MTCR
MH
MEPI
MIL
MNUCPTEREZ
MMAR
MICHAEL
MUNC
MDC
MPOS
MONUC
MAR
MGMT
MAS
MEPN
MENDIETA
MARIA
MONTENEGRO
MOOPS
MSG
MARITIME
MURRAY
MUKASEY
MOTO
MCA
MFO
MEX
MRSEC
MMED
MACP
MAAR
MINUSTAH
MCCONNELL
MAPP
MGT
MARQUEZ
MANUEL
MNUR
MCCAIN
MF
MOHAMMAD
MOHAMED
MNU
MFA
MILITANTS
MINORITIES
MTS
MLS
MILI
MIAH
MEETINGS
MERCOSUR
MED
MARAD
MNVC
MINURSO
MNUCUN
MIK
MARK
MBM
MPP
MILITARY
MAPS
MNUK
MILA
MTRRE
MACEDONIA
MICHEL
MASSMNUC
MUCN
MQADHAFI
MPS
MARRGH
MRCRE
MTRE
MORALES
MAP
MCTRE
MHUC
MOPSGRPARM
MOROCCO
MCAPS
NL
NU
NS
NI
NPT
NATO
NO
NG
NATEU
NSF
NZ
NAS
NP
NDP
NLD
NGO
NEPAD
NAFTA
NASA
NEA
NGUYEN
NIH
NK
NIPP
NONE
NR
NANCY
NEGROPONTE
NRR
NERG
NSSP
NSG
NSFO
NE
NATSIOS
NFSO
NATIONAL
NTDB
NT
NCD
NTSB
NRC
NELSON
NAM
NH
NPG
NEC
NSC
NFATC
NMFS
NATOIRAQ
NAR
NZUS
NARC
NCCC
NA
NC
NEW
NRG
NUIN
NOVO
NATOPREL
NEY
NV
NICHOLAS
NPA
NW
NARCOTICS
NORAD
NOAA
NON
NTTC
NKNNP
NMNUC
NUMBERING
ODIP
OIIP
OPRC
OSCE
OREP
OTRA
OPET
OSCI
OVIP
OECD
OCII
OUALI
OPDC
OEXC
OFPD
OPIC
OFDP
OPCW
OECV
OAS
OM
OMIG
ODAG
OPREP
ORA
OIC
OEXCSCULKPAO
OIG
OASS
OFFICIALS
ORTA
OSAC
OIL
OIE
OEXP
OPEC
OPDAT
OMS
OES
OHI
OMAR
OCRA
OFSO
OCBD
OSTA
OAO
ONA
OTP
ORC
OAU
OXEC
OA
ODPC
OPDP
OVIPPRELUNGANU
OASC
OSHA
OPCD
OTR
OPPI
OPCR
OF
OFDPQIS
OSIC
OHUM
OSTRA
OASCC
OBSP
OFDA
OPICEAGR
OIM
OGAC
OTA
OTRAORP
OPPC
OESC
OCEA
OVP
ON
OPAD
OTAR
OCS
ODC
OTRD
OCED
OSD
ORUE
OREG
PHUM
PINR
PTER
PGOV
PREL
PREF
PL
PM
PHSA
PE
PARM
PINS
PK
PUNE
PO
PALESTINIAN
PU
PBTS
PROP
PTBS
POL
POLI
PA
PGOVZI
POLMIL
POLITICAL
PARTIES
POLM
PD
POLITICS
POLICY
PAS
PMIL
PINT
PNAT
PV
PKO
PPOL
PERSONS
PING
PBIO
PH
PETR
PARMS
PRES
PCON
PETERS
PRELBR
PT
PLAB
PP
PAK
PDEM
PKPA
PSOCI
PF
PLO
PTERM
PJUS
PSOE
PELOSI
PROPERTY
PGOVPREL
PARP
PRL
PNIR
PHUMKPAL
PG
PREZ
PGIC
PBOV
PAO
PKK
PROV
PHSAK
PHUMPREL
PROTECTION
PGOVBL
PSI
PRELPK
PGOVENRG
PUM
PRELKPKO
PATTY
PSOC
PRIVATIZATION
PRELSP
PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ
PMIG
PREC
PAIGH
PROG
PSHA
PARK
PETER
POG
PHUS
PPREL
PS
PTERPREL
PRELPGOV
POV
PKPO
PGOVECON
POUS
PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN
PWBG
PMAR
PREM
PAR
PNR
PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO
PARMIR
PGOVGM
PHUH
PARTM
PN
PRE
PTE
PY
POLUN
PPEL
PDOV
PGOVSOCI
PIRF
PGOVPM
PBST
PRELEVU
PGOR
PBTSRU
PRM
PRELKPAOIZ
PGVO
PERL
PGOC
PAGR
PMIN
PHUMR
PVIP
PPD
PGV
PRAM
PINL
PKPAL
PTERE
PGOF
PINO
PHAS
PODC
PRHUM
PHUMA
PREO
PPA
PEPFAR
PGO
PRGOV
PAC
PRESL
PORG
PKFK
PEPR
PRELP
PREFA
PNG
PGOVPHUMKPAO
PRELECON
PINOCHET
PFOR
PGOVLO
PHUMBA
PRELC
PREK
PHUME
PHJM
POLINT
PGOVPZ
PGOVKCRM
PGOVE
PHALANAGE
PARTY
PECON
PEACE
PROCESS
PLN
PRELSW
PAHO
PEDRO
PRELA
PASS
PPAO
PGPV
PNUM
PCUL
PGGV
PSA
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PGIV
PRFE
POGOV
PEL
PBT
PAMQ
PINF
PSEPC
POSTS
PHUMPGOV
PVOV
PHSAPREL
PROLIFERATION
PENA
PRELTBIOBA
PIN
PRELL
PGOVPTER
PHAM
PHYTRP
PTEL
PTERPGOV
PHARM
PROTESTS
PRELAF
PKBL
PRELKPAO
PKNP
PARMP
PHUML
PFOV
PERM
PUOS
PRELGOV
PHUMPTER
PARAGRAPH
PERURENA
PBTSEWWT
PCI
PETROL
PINSO
PINSCE
PQL
PEREZ
PBS
RS
REFUGEES
RW
RP
RELFREE
RO
REGIONAL
RIGHTS
REACTION
REPORT
RU
RENAMO
RIGHTSPOLMIL
REFORM
RM
REFUGEE
REL
RELATIONS
ROW
RREL
REGION
RATIFICATION
RBI
RICE
ROOD
RODENAS
RUIZ
RODHAM
ROBERT
RGY
ROY
REUBEN
RELIGIOUS
RUEHZO
RODRIGUEZ
RUEUN
RELAM
RSP
RF
RSO
RCMP
REO
ROSS
RPTS
RENE
REID
RUPREL
RMA
RI
REMON
RPEL
RFE
RFIN
RA
RAFAEL
RAY
RUS
RPREL
ROBERTG
RECIN
RAMONTEIJELO
SNAR
SP
SN
SMIG
SL
SOCI
SU
SG
SF
SENV
SZ
SOE
SCUL
SY
SO
SR
SYR
SE
SA
SW
SIPDIS
SCIENCE
SADC
SI
SCI
SOCIETY
SC
SAARC
STR
SECRETARY
SANC
SSH
ST
SNA
SGWI
SEP
SOCIS
SETTLEMENTS
SPECIALIST
SK
SHUM
START
STET
SCVL
SREF
SCHUL
SCUIL
SYRIA
SECURITY
SPCE
SYAI
SMIL
SOWGC
STEPHEN
SNRV
SKCA
SENSITIVE
SECI
SNAP
SPP
SCUD
SOM
SPECI
SMIGBG
SENC
SCRM
SGNV
SECTOR
SENVEAGREAIDTBIOECONSOCIXR
SENVSXE
SASIAIN
SACU
SENVSPL
SWMN
STEINBERG
SOPN
SOCR
SCOI
SCRS
SILVASANDE
SWE
SARS
SNARIZ
SUDAN
SENVQGR
SM
SNARKTFN
SAAD
SD
SAN
SIPRNET
STATE
SENS
SUBJECT
SFNV
SECSTATE
SSA
SPCVIS
SOI
SOFA
SCULKPAOECONTU
SPTER
SKSAF
SENVKGHG
SHI
SEVN
SANR
SPSTATE
SMITH
SCOM
SH
SNARCS
SNARN
SIPRS
SNARM
SIPDI
SCPR
SNIG
SELAB
SULLIVAN
SENVENV
SECDEF
SOLIC
SOIC
SPAS
SASC
SOSI
SEC
SEN
SENVCASCEAIDID
TU
TH
TW
TSPA
TRGY
TPHY
TBIO
TIFA
TS
TZ
TX
TSPL
TT
TK
TC
TINT
TERFIN
TERRORISM
TIP
TURKEY
TI
TECHNOLOGY
TNGD
TRSY
TRAFFICKING
TOPEC
TPSL
TP
TD
TR
TA
TIO
TREATY
TO
THPY
TECH
TRADE
TPSA
TG
TAGS
TF
TRAD
THKSJA
TVBIO
TNDG
TN
TBIOZK
TWI
TV
TWL
TRT
TWRO
TSRY
TTPGOV
TAUSCHER
TRBY
TRBIO
TL
TPKO
TIA
TGRY
TSPAM
TREL
TNAR
TBI
TFIN
TPHYPA
TWCH
THOMMA
THOMAS
TERROR
TRY
TBID
TPP
TE
THANH
TJ
TBKIO
UNGA
USUN
UN
UG
UNSC
UK
UP
US
UNCTAD
UNVIE
UNHRC
USTR
UNAMA
UNCRIME
UNESCO
UV
UNDP
UNHCR
UNCSD
UNCHR
UZ
USAID
UNEP
UNO
UNPUOS
UY
UNDC
UNCITRAL
UNAUS
UNCND
UA
UNMIK
USTDA
USEU
USDA
UNICEF
UR
UNFICYP
USNC
USTRRP
UNODC
UNRWA
UNOMIG
USTRPS
USAU
USCC
UNEF
UNGAPL
UNFPA
UNSCE
USSC
UGA
UEU
UNMIC
UNTAC
UNION
UNCLASSIFIED
USPS
UNA
UMIK
USOAS
UNMOVIC
UNFA
UNAIDS
UNCHC
USGS
UNSE
UNRCR
UNTERR
USG
UE
UAE
UNWRA
UNCSW
UNSCR
UNCHS
UNDESCO
UNPAR
UNC
UB
UNSCS
UKXG
UNGACG
UNREST
UNHR
USPTO
UNFCYP
USCG
UNIDROIT
UNSCD
UPU
UNBRO
UNECE
USTRUWR
UNCC
UNESCOSCULPRELPHUMKPALCUIRXFVEKV
VM
VE
VT
VETTING
VN
VZ
VIS
VC
VTPREL
VIP
VTEAID
VTEG
VOA
VA
VTIZ
VANG
VISIT
VO
VENZ
VAT
VI
VEPREL
VEN
WFP
WTO
WHO
WTRO
WBG
WMO
WIPO
WA
WI
WSIS
WHA
WCL
WE
WMN
WEBZ
WS
WAR
WZ
WMD
WW
WILLIAM
WEET
WAEMU
WM
WWBG
WWT
WWARD
WITH
WMDT
WTRQ
WCO
WEU
WALTER
WRTO
WB
WHTI
WBEG
WCI
WEF
WAKI
WHOA
WGC
Browse by classification
Community resources
courage is contagious
Viewing cable 05BRASILIA1716, BRAZIL GIVES ABBOTT TEN DAYS BEFORE BREAKING PATENT
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #05BRASILIA1716.
| Reference ID | Created | Released | Classification | Origin |
|---|---|---|---|---|
| 05BRASILIA1716 | 2005-06-28 11:04 | 2011-07-11 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Brasilia |
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS SECTION 01 OF 07 BRASILIA 001716
SIPDIS
SENSITIVE
DEPT FOR WHA/BSC, WHA/EPSC, AND EB/TPP/IPE
USAID FOR LAC/SAM
DEPT PLEASE PASS TO USTR FOR SCRONIN, LEYANG, AND BPECK
USDOC FOR 4332/ITA/MAC/WH/OLAC/JANDERSEN/ADRISCOLL/MWAR D
USDOC FOR 3134/ITA/USCS/OIO/WH/RD/DDEVITO/DANDERSON/EOL SON
NSC FOR KBREIER
E.O. 12958: N/A
TAGS: KIPR ETRD IPR
SUBJECT: BRAZIL GIVES ABBOTT TEN DAYS BEFORE BREAKING PATENT
REF: BRASILIA 1507 (NOTAL)
¶1. SENSITIVE BUT UNCLASSIFIED
¶2. (U) Summary. On Friday June 24, the GoB announced a
declaration of "public interest" for Abbott Laboratories AIDS
treatment drug "Kaletra," providing the legal basis for
issuing a compulsory license. The Ministry of Health (MoH)
provided Abbott with 10 days in which to demonstrate that it
would lower its price for Kaletra in order to avoid a
compulsory license. The declaration also noted that
negotiations with Gilead Science, and Merck, Sharp & Dohme
were continuing. End Summary.
¶3. (U) Last week the GoB put into motion a process that will
enable it to compulsory license Kaletra, Abbott Laboratories'
combination Lopinavir/Ritonavir drug for treating AIDS. On
Friday June 24, President Lula and Health Minister Humberto
Costa announced a declaration of "public interest" for
Kaletra, providing the legal basis for issuing a compulsory
license (see para 12 for the text of declaration). The MoH
provided Abbott with 10 days in which to demonstrate that it
would "meet the public interest," i.e. lower its price for
Kaletra in order to avoid a compulsory license. (Only on
Monday, June 27, did Abbott receive a letter officially
notifying it of the GOB's move.) The MoH claims that national
lab Farmaguinhos would be able to produce Kaletra within a
year for a unit price of $0.68 compared to a current unit
price from Abbott of $1.17; the GoB expects Abbott to
continue to supply Kaletra while Farmaguinhos gears up for
production.
¶4. (U) As previously reported, in March, the Ministry of
Health sent letters to three U.S. pharmaceutical companies )
Abbott, Gilead Science, Merck ) threatening compulsory
licensing if they refused to negotiate voluntary licenses for
local production of their anti-AIDS drugs (reftel). In
justifying its actions, the MoH has argued that it must
reduce costs given an expanding patient load in Brazil's
national, free access, HIV/AIDS treatment program, noting
that the three drugs produced by these companies account for
roughly 66 percent of the GoB's budget for anti-retrovirals.
All three companies have been negotiating with the MoH over
the past several months, but with different approaches.
¶5. (SBU) Friday's declaration stated that negotiations with
Gilead and Merck are still continuing and singled out Abbott
as the only one to have refused negotiations on both
voluntary licensing and price. The main thrust of Abbott's
strategy to date has been to highlight its plans for a $53
million investment for local production, although in
conversations with Emboffs Abbott reps did note that several
months ago they had offered the GOB price reductions of 11 to
12 percent in their yearly negotiations. Gilead prepared a
proposal addressing reliability of supply and price issues;
we do not have details of the last Merck proposal.
¶6. (SBU) Post has been in contact with the companies since
the declaration; all are still evaluating the latest GoB
action and considering next steps. However, we understand
that Merck is contemplating taking a hard-line; refusing to
cooperate with the GoB should it move to break any company's
patent, not just Merck's. Merck's local rep has a meeting
scheduled with Vice-Minister of Health Barbosa on Wednesday,
June 29 and we will seek to find out how that session goes.
¶7. (U) According to Brazil's legislation and regulations, a
compulsory license may be issued for reasons of national
emergency or public interest; if invoked for reasons of
public interest, use of the compulsory license is restricted
to "non-commercial use" (see para 13 for an unofficial
translation of Decree 3,201/1999, as revised by Decree
4,830/2003).
¶8. (SBU) There are several interesting points regarding the
MoH's June 24 declaration, first among them, Brazil's
decision to use "public interest" instead of national
emergency as the basis for a potential compulsory license.
Over the past several weeks, the pharmaceutical industry and
intellectual property rights interest groups have criticized
Brazil over its compulsory licensing threat arguing the
absence of a national emergency given Brazil's low 0.6
percent incidence rate for AIDS and its status as an advanced
developing country. By using a "public interest" argument,
the GoB avoids having to refute such criticism. According to
Brazilian regulation, using this basis also limits production
to non-commercial use. The declaration also states
explicitly that production would be to supply the domestic
market only, not for export.
¶9. (SBU) Comment: Given the formulation of the MoH
declaration, it appears as if the GoB is being careful to
construct a path toward compulsory licensing that it believes
is within the bounds of the TRIPS Agreement. However, we
anticipate that Abbott would argue that the royalty payment
offered by the GoB under a compulsory license would be
inadequate; according to press reports, the GoB plans to
offer a royalty of 3 percent based on the GoB's cost of
production.
¶10. (U) Furthermore, the GoB's bottom line ) i.e.,
compulsory licensing no matter what or whether adequate
reductions in price would stave off this threat ) is still
unclear. Press reports over the weekend quote Costa as
saying that the GoB is not interested in breaking patents,
but in guaranteeing supply of medicines for the national
treatment program. On the other hand, he is also quoted as
saying that the decision to compulsory license has been made,
and that the June 24 declaration was a "mere formality."
Meanwhile, according to the local press, Costa ) who after
the June 24 declaration headed off to Geneva for a UNAIDS
meeting ) has been recalled to Brasilia by President Lula.
Speculation is that Lula will announce a ministerial reform,
which will involve Costa departing the Ministry (for reasons
unrelated to AIDs patents) ) to prepare for an expected run
for Governor of Pernambuco state.
¶11. (SBU) Post is attempting to contact GoB interlocutors
who may be able to shed light on the current thinking within
the government, a task complicated by an impending cabinet
shuffle; we suspect that the economic ministries may not have
had been involved the decision to issue the declaration. We
hope to gain insight into GoB intentions toward Gilead and
Merck; our understanding is that these companies have not
been contacted recently by the MoH and given the Abbott
declaration are grappling with what should be their next
move. Post will report additional information as it becomes
available and requests relevant guidance from Washington
agencies.
¶12. (U) June 24 Declaration of Public Interest (English
version as given on the MoH website, with divergence from
Portuguese version noted):
"The Ministry of Health of Brazil has declared the
anti-retroviral drug Kaletra (Lopinavir/ritonavir),
manufactured by Abbott Laboratories, to be of public
interest. (The Portuguese version of the previous sentence
states specifically that "The President of the Republic, Luiz
Inacio Lula da Silva, and the Ministry of Health, Humberto
Costa" made the declaration.) As such, the Brazilian
government will adopt obligatory licensing of the medication,
in the case that the manufacturer does not provide the
necessary requirements to guarantee the sustainability of the
National STD/AIDS Program.
An official notice sent this Friday to the Laboratory opens
the door for the company to express its opinion on whether it
will address this situation in the public's interest.
The Laboratory will have 10 days from receipt of this notice
to inform the Brazilian Ministry of Health that it is
prepared to reduce the sales price of Kaletra to national
production levels. (The Portuguese version of the previous
sentence states the company has 10 days to inform the
Ministry of Health is it is disposed to respond to the public
interest ) it does not explicitly refer to a reduction in
the Kaletra sales price to national production levels.) Its
agreement will prevent the adoption of obligatory licensing.
With the licensing, the government will be able to allow
Farmanguinhos Laboratory, from Fiocruz (Oswaldo Cruz
Foundation), to produce the medicine for exclusive public,
and not commercial, use. This measure is necessary to
maintain the sustainability and the quality of the National
STD/AIDS Program, which is responsible for guaranteeing life
for close to 170,000 Brazilians this year.
With the declaration of public interest, the Brazilian
government is applying the flexibility laid out in
international norms and Brazilian legislation, without
breaking a contract. (The previous sentence in the
Portuguese version is as follows: The declaration of public
interest will be instituted by means of a "Portaria
Ministerial" (Ministerial decree/regulatory order), signed
this Friday.) The Ministry of Health is basing its
adoption of the licensing on the TRIPs Accords (Trade-Related
Aspects of Intellectual Property Rights), the Doha
Declaration, the Patent Law (1996) and Decree 4.830/03.
The Brazilian National STD/AIDS Program is a worldwide
benchmark for treatment of HIV carriers and has as its goals
the universal and free access to all resources available for
the treatment of the disease, and for prevention and
diagnosis at public hospitals.
The number of patients using anti-retrovirals in Brazil has
risen from nearly 36,000 in 1997 to 170,000. Between 2004
and 2005, more than 20,000 people participated in the
Program. There are 15 types of anti-retroviral medications
that distributed free of charge. Kaletra was introduced in
2002 and is prescribed for patients who have already
developed resistance to other medications.
(Portuguese version of the last two paragraphs reads as
follows : The National Program for Sexually Transmitted
Diseases (STDs)/Aids, a global benchmark for the treatment of
HIV carriers, incorporated around 20,000 more people between
2004-2005 for the treatment with an anti-aids cocktail. With
this, the number of those benefiting will rise from 147,000
to 170,000 by the end of this year.)
To guarantee the use of the latest generation
anti-retrovirals on all people, the Ministry of Health has
increased by 50% the resources dedicated to the program,
which started in 2004 at R$620.9 million, and in 2005 were
increased to R$945 million (US$393.9 million). Of this sum,
almost one third (R$257 million) will be used solely for the
acquisition of Kaletra.
The projection is that in 2008, close to 215,000 people in
Brazil will need the cocktail, which means a budget of R$1.25
billion (US$520.8 million), with one third of this amount
being earmarked for the purchase of Kaletra.
Investment increases to maintain the National STD/AIDS
Program have been constant. But in the last four years,
Brazil has increased investments by 77%, while the number of
patients has gone up by 43%.
It is estimated that 600,000 Brazilians carry the HIV virus.
There are even more who do not know that they are infected,
and will need to be treated in the upcoming years. "Brazil
is concerned about doing a good job of treating those
Brazilians who need it, with the proper medication, and with
updated treatment measures. It is a matter of public
interest", explains Minister Humberto Costa. (This last
sentence is not in the Portuguese version).
To guarantee delivery of the ideal medicine to each one of
the carriers registered in the program, the Ministry of
Health must acquire the latest generation medications.
Beginning to be distributed, for example, is Enfuvirtida,
which belongs to a new class of anti-retrovirals, at a cost
of R$19,000/month (US$7,900 per patient). A total of 1,200
patients are currently signed up to be treated with this new
medication.
Negotiation - In March of this year, the Ministry began
negotiations for voluntary licensing with Abbott
Laboratories, Gilead Science Incorporation, and Merck Sharp &
Dohme. The medications produced by these laboratories -
Kaletra, Efavirenz (Merck) and Tenofovir (Gilead) - make up
66% of the entire budget for the purchase of
anti-retrovirals.
Negotiations with Merck and Gilead continue. Abbott was the
only one to oppose both the alternative voluntary licensing
as well as a price reduction which guarantees the future
sustainability of the program. Since the medication arrived
in Brazil in 2002, its price has been reduced by 25%--a
percentage that is considered to be low in global
terms--because development costs diminish over the years.
Today, the unit price of Kaletra is US$1.17 in contrast to
its price of US$1.60 in 2002, and US$0.72 for its generic
version. However, in this period, the government costs for
the purchase of the medication have gone up from US$35.2
million to $91.6 million annually. This is due to the fact
that the number of patients who need the medication in Brazil
has increased threefold per year. In 2002, there were 3,200
people who needed it. This year, there will be 23,400.
Legislation - The Ministry of Health's initiative is backed
by national and international norms and respects the rights
of private companies to make a profit from their inventions.
Article 71 of Brazilian patent law (Law 9.279/96) provides
for obligatory licensing in the case of public interest.
Decrees 3201 of 1999, and 4830 of 2003, also consider those
items related to public health to be of public interest.
The Doha Declaration (Qatar) in 2001 allows countries to take
measures to protect public health. Those measures, according
to the Declaration, do not compromise the TRIPs Agreement,
which established minimum rights over intellectual property.
Should Abbott Laboratories not follow the Ministry's notice,
the medication will be produced in Brazil exclusively for
national consumption. (The Portuguese version of the
previous sentence reads as follows: The Ministry of Health,
in accordance with the legislation, will be able to grant the
license for the production of Lopinavir/ritonavir, only for
national consumption and will pay royalties to Abbott.)
Although the obligatory licensing gives Brazilian
laboratories the right to produce Liponavir/ritonavir, it
does not prevent Abbott from commercializing Kaletra in the
country.
National production - With the obligatory licensing, the
Institute of Pharmaceutical Technology (Farmanguinhos
Laboratory), of the Oswaldo Cruz Foundation would produce the
Lopinavir/ritonavir medication while reducing by the current
price by almost 50%. Within one year, Farmaguinhos would be
able to produce six million capsules/month, the necessary
amount to meet domestic demand. The unit price for the
medication should be around US$0.68, which would add up to
approximately R$130 million/year (in savings)for the National
Program.
Farmaguinhos is the largest official laboratory in Brazil and
already produces more than 60 medicines, among them
anti-retrovirals. Last year, the Brazilian government
invested US$6 million in the acquisition of the
GlaxoSmithKline industrial park in Rio de Janeiro in order to
convert it into the Medicine Technology Complex (CTM) for
Farmaguinhos. The CTM will produce 10 billion pharmaceutical
units in 2007.
The Program - Since 1986, the National STD/AIDS Program has
guaranteed 100% free treatments to those with HIV/AIDS.
Since the program started, the life expectancy of persons
with AIDS has increased twelve-fold, from five months to 58
months. Mortality has dropped 50% and the number of pregnant
women suffering from the disease who have access to AZT,
which helps prevent infection of the newborn, is on the rise.
This year, the Ministry of Health will finance 754
disease-fighting projects run by NGOs with a budget of R$60
million.
These last two paragraphs were added to the English version:
In 2001, UNESCO (United Nations Educational, Scientific, and
Cultural Organization) presented an award to the Brazilian
program in the category of Human Rights and Culture of Peace.
Last year, the quality of the Brazilian AIDS Program
received one more international award: a medal from the U.N.
AIDS Program (UNAIDS) for the leadership that Brazil has
exerted in improving the fight against the epidemic.
Brazil has participated in an international HIV and AIDS
cooperation program since 1995. Today, 25 countries are
involved in that work, which includes prevention, assistance
and treatment, epidemiological monitoring, project
management, sexually transmitted diseases, human rights, and
cooperation with private sector organizations.
¶13. Decree 3,201 (October 6, 1999) with revisions as
provided by Decree 4,830 (September 4, 2003) (unofficial
translation):
DECREE No. 3,201 OF OCTOBER 6, 1999
Establishes rules concerning the granting, ex officio, of
compulsory licenses in cases of national emergency and public
interest provided for in Article 71 of Law no. 9,279, of May
14,1996.
THE PRESIDENT OF THE REPUBLIC, using the prerogatives to
which he is entitled by Article 84, Item IV, of the
Constitution, and in consideration of the provisions of
Article 71 of Law no. 9,279, of May 14, 1996.
DECREES:
Article 1. The granting, ex officio, of a compulsory license
in cases of national emergency or public interest, in the
latter case only for non-commercial public use, that provided
for in Article 71 of Law no. 9,279, of May 14, 1996, shall be
ruled in accordance with this Decree.
Article 2. There may be granted, ex officio, a compulsory
license for a patent in cases of national emergency or public
interest, in the latter case only for non-commercial public
use, as thus declared by the Government, when it is
ascertained that the patent-holder, directly or by licensee
intermediary, does not fulfill those needs.
Paragraph 1. A national emergency is understood to be a
condition of impending danger to the public, even if existing
only in a part of the national territory.
Paragraph 2. There are considered to be within the public
interest those facts, among others, related to the public
health, nutrition, protection of the environment, as well as
those of primordial importance to the technological or social
and economic development of the Country.
Article 3. The act of the Federal Executive Power declaring
the national emergency or the public interest shall be
performed by the Minister of State responsible for the
subject matter in question and shall be published in the
Federal Official Gazette.
Article 4. There having been ascertained the impossibility of
the patent-holder or his licensee to fulfill the national
emergency or public interest situation, the Government shall
grant, ex officio, the compulsory license, which shall not be
exclusive, and the respective act shall be immediately
published in the Federal Official Gazette.
Article 5. The act of granting the compulsory license will
establish, among others, the following conditions:
I ) the term of the license and the possibility of renewal;
and
II ) those offered by the Union, particularly regarding the
compensation to the titleholder.
Paragraph 1. The act of granting the compulsory license can
also establish the obligation of the titleholder to transmit
the necessary and sufficient information to the effective
reproduction of the protected object and the rest of the
applicable technical aspects to the case in question, noting
that, in case of denial, what was provided by article 24 and
Title I, Chapter VI, of Law 9,279 of 1996.
Paragraph 2. In order to determine the compensation to which
the titleholder is entitled, there shall be considered the
relevant economic and market circumstances, the price of
similar products and the economic value of the authorization.
Article 6. The competent authority may request information as
needed to support the granting of the license or to determine
the compensation due to the patent-holder, as well as other
pertinent information, to the federal, state and municipal,
direct and indirect, public administration agencies and
entities.
Article 7. In case of national emergency or public interest
characterizing extreme urgency, the compulsory license
provided for in this Decree may be implemented and the use of
the patent may be effected, irrespective of prior compliance
with the conditions established in Articles 4 and 5 of this
Decree.
Sole Paragraph. If the competent authority has knowledge,
without conducting a search, of the existence of a patent in
force, the titleholder shall be immediately informed on such
use.
Article 8. The exploitation of a compulsorily licensed patent
in accordance with the provisions of this Decree may be
initiated irrespective of the existence of an agreement on
the conditions included in Article 5.
Article 9. The exploitation of a patent licensed in
accordance with the provisions of this Decree may be
performed directly by the Union or by duly contracted third
parties or by partners, and the reproduction of the object
thereof for other purposes being prohibited, under penalty of
being considered illicit.
Sole Paragraph. The exploitation by third parties of the
compulsorily licensed patent shall be made in compliance to
the principles of Article 37 of the Constitution, noting the
additional pertinent legal rules.
Article 10. In such cases where it might not be possible to
fulfill the situations of national emergency or public
interest with the product placed on the domestic market, or
the manufacture of the object of the patent by third parties,
or by the Union, is found to be unfeasible, the latter may
proceed to import the product that is the object of the
patent.
Sole Paragraph. In the cases mentioned within the heading
paragraph of this article, the Union shall either preferably
acquire the product which has been placed directly into the
market by its titleholder or with the latter's consent, since
such procedure does not frustrate the purposes of the license.
Article 12. Once the national emergency or the public
interest has been fulfilled, the competent authority shall
extinguish the compulsory license, respecting the terms of
the contract executed with the licensee. (Note, Article 11 of
the 1999 Decree was dropped.)
Article 13. The competent authority shall inform the
Instituto Nacional da Propriedade Industrial ) INPI
(National Institute of Industrial Property), for purposes of
entry, the licenses for noncommercial public use, granted on
the basis of Article 71 of Law no. 9,279, of 1996, as well as
the changes and extinguishment of such licenses.
Article 14. This Decree enters into force on the date of its
publication.
Brasilia, October 6, 1999; 178th year of Independence, 111th
year of the Republic.
FERNANDO HENRIQUE CARDOSO
Jose Serra
Alcides Lopes Tapias
Danilovich